DL-Pyroglutamic acid
Need Assistance?
  • US & Canada:
    +
  • UK: +

DL-Pyroglutamic acid

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Pyroglutamic acid (also known as PCA, 5-oxoproline, pidolic acid, or pyroglutamate for its basic form) is an uncommon and little studied amino acid derivative in which the free amino group of glutamic acid or glutamine cyclizes to form a lactam. It is a metabolite in the glutathione cycle that is converted to glutamate by 5-oxoprolinase. Pyroglutamate is found in many proteins including bacteriorhodopsin. N-terminal glutamic acid and glutamine residues can spontaneously cyclize to become pyroglutamate. This is one of several forms of blocked N-terminals which present a problem for N-terminal sequencing using Edman chemistry, which requires a free primary amino group not present in pyroglutamic acid. The enzyme pyroglutamate aminopeptidase can restore a free N-terminus by cleaving off the pyroglutamate residue.

Category
Cyclic Amino Acids
Catalog number
BAT-005285
CAS number
149-87-1
Molecular Formula
C5H7NO3
Molecular Weight
129.11
DL-Pyroglutamic acid
IUPAC Name
5-oxopyrrolidine-2-carboxylic acid
Synonyms
5-oxoproline; DL-2-Pyrrolidone-5-carboxylic acid; DL-Pyroglutamic acid; 2-Pyrrolidone-5-carboxylic acid; 5-Oxopyrrolidine-2-carboxylic Acid
Appearance
White Crystalline Powder
Purity
≧ 95%
Density
1.380 g/cm3
Melting Point
183-185 °C (lit.)
Boiling Point
239.2 °C
Storage
Store at 2-8 °C
InChI
InChI=1S/C5H7NO3/c7-4-2-1-3(6-4)5(8)9/h3H,1-2H2,(H,6,7)(H,8,9)
InChI Key
ODHCTXKNWHHXJC-UHFFFAOYSA-N
Canonical SMILES
C1CC(=O)NC1C(=O)O
1.[5-0xoproline (pyroglutamic acid) acidosis and acetaminophen- a differential diagnosis in high anion gap metabolic acidosis].
Weiler S1, Bellmann R2, Kullak-Ublick GA1. Ther Umsch. 2015 Dec;72(11-12):737-41. doi: 10.1024/0040-5930/a000745.
Rare cases of high anion gap metabolic acidosis during long-term paracetamol administration in therapeutic doses with causative 5-oxoproline (pyroglutamic acid} accumulation have been reported. Other concomitant risk factors such as malnutrition, alcohol abuse, renal or hepatic dysfunction, comedication with flue/oxacillin, vigabatrin, netilmicin or sepsis have been described. The etiology seems to be a drug-induced reversible inhibition of glutathione synthetase or 5-oxoprolinase leading to elevated serum and urine levels of 5-oxoproline. Other more frequent differential diagnoses, such as intoxications, ketoacidosis or lactic acidosis should be excluded. Causative substances should be stopped. 5-oxoproline concentrations in urine can be quantified to establish the diagnosis. Adverse drug reactions, which are not listed or insufficiently described in the respective Swiss product information, should be reported to the regional pharmacovigilance centres for early signal detection.
Online Inquiry
Verification code
Inquiry Basket